feed,title,long_url,short_url
Benzinga,Potential Upside For Eiger's Avexitide In Both PBH And CHI Indications: Analyst,https://benzinga.com/analyst-ratings/analyst-color/23/06/33082155/potential-upside-for-eigers-avexitide-in-both-pbh-and-chi-indications-analyst,https://da.gd/DDBCNL
Benzinga,Genfit's Miss Is CymaBay Therapeutics' Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-Class,https://benzinga.com/analyst-ratings/analyst-color/23/06/33082891/genfits-miss-is-cymabay-therapeutics-gain-analyst-says-rival-data-leaves-room-for-s,https://da.gd/VlUlWl
